Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising outcomes in initial human trials . Ongoing inquiry https://tealbookmarks.com/story21342154/retatrutide-emerging-research-and-potential-therapeutic-applications